CAR-NK production for clinical applications using BaEV lentivirus and the NK cell engineering platform
Jul
10
2024
Upcoming webinar

CAR-NK production for clinical applications using BaEV lentivirus and the NK cell engineering platform

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
CAR-NK production for clinical applications using BaEV lentivirus and the NK cell engineering platform

Engineered NK cells are an exciting new therapeutic modality; however, technical challenges have hindered clinical success. Lentiviral vector transduction is a well-established step in producing CAR-T cell therapies, but traditional lentiviral vectors are not well suited to NK cells and yield poor transduction efficiency.

Baboon envelope glycoprotein pseudotyped lentiviral vector (BaEV-LV) has been shown to have robust transduction potential and, in a recent study, it performed better than vesicular-stomatitis-virus-G protein lentiviral vector (VSV-G-LV) in transducing primary NK cells.

Building on those results, this webinar presents new data on BaEV-LV transduction efficiency generated using the CliniMACS Prodigy® NK Cell Engineering platform. The NK cells were isolated first by depletion of CD3+ cells, followed by enrichment of CD56+ cells, then transduced with a BaEV encoding a CAR transgene, and expanded on the Prodigy system in a closed and automated process. These results strongly indicate that BaEV-LV provides superior transduction efficiency, and CAR-NK cell manufacturing with CliniMACS Prodigy generates highly pure CAR-NK cells with potent cytotoxic functionality.

Join the webinar to learn more about:

  • The benefits of BaEV lentiviral vector transduction of NK cells
  • How to implement the CliniMACS NK cell engineering process
  • Utilizing the NK flow cytometry Express Modes on the MACSQuant Analyzer
  • Leveraging Miltenyi Bioindustry expertise in analytical development
Han-Hsuan Fu
Han-Hsuan Fu
Senior Scientist at Miltenyi Biotec

In her current role, Dr. Fu coordinate the establishment CliniMACS Prodigy platform for Cell & Gene Therapy at the Miltenyi Gaithersburg, Maryland site. The expansion of this platform enhances client-based work offered for scalability and shortened product transit time.

Her previous work on the immune-based treatment of solid tumors and blood cancers, using tumor specific T cells at Johns Hopkins University. The studies led to numerous funding and saw an expansion of the program. Another area she studied was the bone marrow transplant induced immune responses, such as graft-versus-host disease. This work could alleviate complications during treatment.

Dr. Fu’s thesis work at University of Connecticut on T cell memory formation increased the level of understanding of T cell clonal expansion and the subpopulations of based on the signals received during development.